FDA clears Imaging Therapeutics hip bone mineral density system
Imaging Therapeutics has received marketing clearance from the FDA to market its OsDx hip bone mineral density (BMD) system.
The company said its OsDx Hip BMD is a stand-alone x-ray image-processing software system intended to provide an estimate of BMD of the proximal femur using standard antero-posterior hip or pelvis radiographic images. The information may be used by physicians in the assessment of osteoporosis.
The technology permits BMD testing to be performed using any conventional x-ray system, according to the Redwood City, Calif.-based Imaging Therapeutics.
The company said its OsDx Hip BMD is a stand-alone x-ray image-processing software system intended to provide an estimate of BMD of the proximal femur using standard antero-posterior hip or pelvis radiographic images. The information may be used by physicians in the assessment of osteoporosis.
The technology permits BMD testing to be performed using any conventional x-ray system, according to the Redwood City, Calif.-based Imaging Therapeutics.